Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on developing innovative therapies for unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has ...

The investigational orexin receptor 2 (OX2R) agonist oveporexton improved cognitive symptoms of narcolepsy type 1 (NT1) in secondary analysis of a phase II trial.

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive daytime ...

Takeda has said it intends to move quickly ahead with regulatory filings for oveporexton, its orexin agonist for sleep disorder narcolepsy, after a clean sweep of positive efficacy data in two phase 3 ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) recently reported encouraging data from its pivotal bioequivalence study for pitolisant gastro-resistant (GR), marking a major milestone as the ...